PTC Therapeutics Inc [PTCT] stock is trading at $47.39, up 2.11%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The PTCT shares have gain 17.62% over the last week, with a monthly amount drifted -16.83%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
PTC Therapeutics Inc [NASDAQ: PTCT] stock has seen the most recent analyst activity on March 11, 2025, when BofA Securities upgraded its rating to a Neutral and also boosted its price target to $55 from $41. Previously, Scotiabank started tracking the stock with Sector Perform rating on March 07, 2025, and set its price target to $55. On December 13, 2024, upgrade upgraded it’s rating to Overweight and revised its price target to $67 on the stock. RBC Capital Mkts upgraded its rating to a Outperform and increased its price target to $63 on December 03, 2024. Robert W. Baird started tracking with a Outperform rating for this stock on September 04, 2024, and assigned it a price target of $44.
PTC Therapeutics Inc [PTCT] stock has fluctuated between $24.00 and $58.38 over the past year. Currently, Wall Street analysts expect the stock to reach $55 within the next 12 months. PTC Therapeutics Inc [NASDAQ: PTCT] shares were valued at $47.39 at the most recent close of the market. An investor can expect a potential return of 16.06% based on the average PTCT price forecast.
Analyzing the PTCT fundamentals
PTC Therapeutics Inc [NASDAQ:PTCT] reported sales of 806.78M for the trailing twelve months, which represents a drop of -30.58%. Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -0.37%, Pretax Profit Margin comes in at -0.45%, and Net Profit Margin reading is -0.45%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is 0.36 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -2.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 46.24 points at the first support level, and at 45.09 for the second support level. However, for the 1st resistance point, the stock is sitting at 48.25, and for the 2nd resistance point, it is at 49.11.
Ratios To Look Out For
For context, PTC Therapeutics Inc’s Current Ratio is 2.35. Further, the Quick Ratio stands at 2.31, while the Cash Ratio is 1.34. Considering the valuation of this stock, the price to sales ratio is 4.63.
Transactions by insiders
Recent insider trading involved Golden Lee Scott, EVP & CHIEF MEDICAL OFFICER, that happened on Apr 02 ’25 when 897.0 shares were sold. Officer, Golden Lee Scott completed a deal on Apr 02 ’25 to buy 897.0 shares. Meanwhile, CHIEF BUSINESS OFFICER Pauwels Eric sold 6762.0 shares on Mar 17 ’25.
